Biblio Discovery — Demo Discovery Service

3 results for "Mark C. Mattar"

Showing 1–3 · 0.14 seconds · RSS

  1. Journal Article Full text

    Peroxisome proliferator-activated receptors in inflammatory bowel disease: linking immunometabolism, lipid signaling, and therapeutic potential

    Kiandokht Bashiri; Mark C. Mattar; Alireza Meighani et al.

    Intestinal Research, Vol. 24 No. 1 · 2026 · English · DOAJ Scopus

    Inflammatory bowel disease (IBD), encompassing Crohn’s disease (CD) and ulcerative colitis, is a chronic condition marked by immune dysregulation, genetic predisposition, and metabolic disturbances. Emerging evidence highlights the role of lipid metabolism and peroxisome proliferator-activated…

  2. Journal Article

    Artificial intelligence in inflammatory bowel disease endoscopy: current landscape and the road ahead

    Suneha Sundaram; Tenzin Choden; Mark C. Mattar et al.

    Therapeutic Advances in Gastrointestinal Endoscopy, Vol. 14 · 2021 · English · DOAJ Scopus

    Inflammatory bowel disease is a complex chronic inflammatory disorder with challenges in diagnosis, choosing appropriate therapy, determining individual responsiveness, and prediction of future disease course to guide appropriate management. Artificial intelligence has been examined in the field of…

  3. Journal Article

    Treat-to-target of endoscopic remission in patients with inflammatory bowel disease in symptomatic remission on advanced therapies (QUOTIENT): rationale, design and protocol for an open-label, multicentre, pragmatic, randomised controlled trial

    Sagar Patel; Vipul Jairath; Guangyong Zou et al.

    BMJ Open Gastroenterology, Vol. 12 No. 1 · 2025 · English · DOAJ Scopus

    Introduction Targeted immunomodulators (eg, advanced therapies) effectively achieve symptomatic remission in patients with inflammatory bowel disease (IBD). However, ~25%–50% of patients with IBD achieving symptomatic remission with an advanced therapy may have continued…